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Hereditary angioedema with C1 inhibitor deficiency (C1‐INH‐HAE) is a rare autosomal dominant disorder due to either deficiency (type I, 85% of cases) or dysfunction (type II, 15% of cases) of the serine protease inhibitor (serpin) C1 inhibitor (C1‐INH). A less common form of hereditary angioedema has a positive family history, but normal C1‐INH protein quantity and function: In some cases, the disease appears to be related to factor *F12* gene defects (FXII‐HAE), while in most cases, the cause of this form of angioedema remains unknown (U‐HAE). This consensus addresses only C1‐INH‐HAE in the pediatric ages of birth until 18th birthday. Angioedema is due to the leakage of plasma from postcapillary venules mediated by the unregulated generation of bradykinin [1](#all13001-bib-0001){ref-type="ref"}. C1‐INH‐HAE is characterized by recurrent attacks of nonpruritic, nonpitting subcutaneous, and/or submucosal angioedema that can affect any part of the body. Publications on clinical manifestations combining pediatric and adult patients show that skin involvement is the most frequent location of the edema (91% of patients) followed in frequency by abdominal attacks (73%) and upper airway edema (48%) [2](#all13001-bib-0002){ref-type="ref"}. Viewing per‐episode, nearly all episodes consisted of skin swellings and abdominal attacks (96.5%). Per‐episode, laryngeal events are rare (0.9%), but potentially life threatening [3](#all13001-bib-0003){ref-type="ref"}. One‐third of patients may develop an erythematous, nonpruritic rash, erythema marginatum, which might precede or accompany angioedema, although it can also occur independently [4](#all13001-bib-0004){ref-type="ref"}. Sudden swellings of the gastrointestinal mucosa are common and often associated with severe debilitating abdominal pains. In one‐quarter of patients, severe abdominal pain may be the initial symptom. Acute abdominal pain mimics acute abdomen and may lead to unnecessary abdominal surgery. Edema involving the submucosa of the upper airways may cause airway obstruction and without treatment may lead to suffocation and death. The reported age of onset of attacks varies from 4.4 to 18 years with mean age of first attack at the age of ten [3](#all13001-bib-0003){ref-type="ref"}, [5](#all13001-bib-0005){ref-type="ref"}, [6](#all13001-bib-0006){ref-type="ref"}, [7](#all13001-bib-0007){ref-type="ref"}, [8](#all13001-bib-0008){ref-type="ref"}, [9](#all13001-bib-0009){ref-type="ref"}, [10](#all13001-bib-0010){ref-type="ref"}, [11](#all13001-bib-0011){ref-type="ref"}, [12](#all13001-bib-0012){ref-type="ref"}, [13](#all13001-bib-0013){ref-type="ref"}. Early onset of symptoms may predict a more severe course of disease [3](#all13001-bib-0003){ref-type="ref"}, [14](#all13001-bib-0014){ref-type="ref"}, [15](#all13001-bib-0015){ref-type="ref"}. HAE attacks usually become more severe at puberty particularly in females and swellings may occur for the first time with the introduction of estrogen‐containing medications [16](#all13001-bib-0016){ref-type="ref"}, [17](#all13001-bib-0017){ref-type="ref"}. The diagnosis of C1‐INH‐HAE is often delayed for years because of the rarity of the disease and of the fact that its symptoms overlap with those of other forms of angioedema. The time between the onset of symptoms and diagnosis averages 8.5 years [18](#all13001-bib-0018){ref-type="ref"}. The diagnosis of C1‐INH‐HAE type II may be limited by the availability of testing for functional C1‐INH level. In patients without a positive family history or with C1‐INH‐HAE type II, delay in diagnosis is usually longer [6](#all13001-bib-0006){ref-type="ref"}, [9](#all13001-bib-0009){ref-type="ref"}, [11](#all13001-bib-0011){ref-type="ref"}, [12](#all13001-bib-0012){ref-type="ref"}, [18](#all13001-bib-0018){ref-type="ref"}, [19](#all13001-bib-0019){ref-type="ref"}, [20](#all13001-bib-0020){ref-type="ref"}. The utility of antifibrinolytics and androgens in C1‐INH‐HAE prophylaxis and plasma‐derived C1‐INH (pdC1‐INH) in replacement therapy have long been recognized. In recent years, other novel therapies have become available with efficacy proven by double‐blind studies mostly conducted in adults. International consensus publications on HAE have mostly been relevant to adult C1‐INH‐HAE [21](#all13001-bib-0021){ref-type="ref"}, [22](#all13001-bib-0022){ref-type="ref"}, [23](#all13001-bib-0023){ref-type="ref"}. Pediatric‐focused international consensus for the diagnosis and management of C1‐INH‐HAE patients has not been previously published. This report presents international consensus for the diagnosis and management of C1‐INH‐HAE in the pediatric age group.

Methods {#all13001-sec-0006}
=======

Bibliographic search {#all13001-sec-0007}
--------------------

### Data sources {#all13001-sec-0008}

A PubMed search (last updated December 31, 2015) was performed using the following key words: hereditary angioedema, C1 inhibitor, C1 inhibitor deficiency, pediatrics, adolescence, children, diagnosis, treatment, consensus, guidelines; additional titles from the reference lists of published articles in English language; additional data from abstracts known to the authors.

Discussion {#all13001-sec-0010}
----------

An expert panel meeting and Round Table discussion took place during the 9th C1 Inhibitor Deficiency Workshop in Budapest on May 30, 2015 ([www.haenet.hu](http://www.haenet.hu)). Data were presented followed by discussion and consensus was determined by voting.

Evidence level {#all13001-sec-0011}
--------------

The levels of evidence to support the views expressed in this document will be indicated in accordance with the *U*.S. Preventive Services Task Force Guidelines for ranking evidence on the effectiveness of treatments or screening, U.S. Preventive Services Task Force, August 1989 (Guide to clinical preventive services: Report of the U.S. Preventive Task Force. DIANE Publishing. p. 24. ISBN 9781568062976) (Table [1](#all13001-tbl-0001){ref-type="table-wrap"}).

###### 

Levels of evidence (U.S. Preventive Services Task Force for ranking evidence about the effectiveness of treatments or screening)

  Levels                                                                                     Description
  ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------
  I                                                                                          Evidence obtained from at least one properly designed randomized controlled trial.
  II‐1                                                                                       Evidence obtained from well‐designed controlled trials without randomization.
  II‐2                                                                                       Evidence obtained from well‐designed cohort or case--control analytic studies, preferably from more than one center or research group.
  II‐3                                                                                       Evidence obtained from multiple time series with or without the intervention.
  Dramatic results in uncontrolled trials might also be regarded as this type of evidence.   
  III                                                                                        Opinions of respected authorities, based on clinical experience
  Descriptive studies                                                                        
  Reports of expert committees                                                               

John Wiley & Sons, Ltd

Results {#all13001-sec-0012}
=======

Clinical symptoms {#all13001-sec-0013}
-----------------

Similar to adults, clinical events in pediatric patients with C1‐INH‐HAE are characterized by recurrent subcutaneous and/or submucosal edematous episodes without wheals or pruritus, and if untreated, the edema may persist for 1 to 5 days before resolving spontaneously [24](#all13001-bib-0024){ref-type="ref"}.

### Onset of symptoms {#all13001-sec-0014}

In C1‐INH‐HAE, attacks may occur at any age after birth, but *in utero* angioedema symptoms have not been reported. The presence of a fetus with C1‐INH‐HAE may affect the number of maternal attacks [25](#all13001-bib-0025){ref-type="ref"}, [26](#all13001-bib-0026){ref-type="ref"}. The nature of C1‐INH transport across the placental barrier is unclear, but likely requires active transport. Although C1‐INH deficiency is present at birth, clinical symptoms are rare during infancy. Newborns may experience erythema marginatum as a prodromal symptom, but rarely swelling [4](#all13001-bib-0004){ref-type="ref"}, [27](#all13001-bib-0027){ref-type="ref"}. The reported age of onset of attacks varies from 4.4 to 18 years with mean age of first attack at the age of ten [3](#all13001-bib-0003){ref-type="ref"}, [5](#all13001-bib-0005){ref-type="ref"}, [6](#all13001-bib-0006){ref-type="ref"}, [7](#all13001-bib-0007){ref-type="ref"}, [8](#all13001-bib-0008){ref-type="ref"}, [9](#all13001-bib-0009){ref-type="ref"}, [10](#all13001-bib-0010){ref-type="ref"}, [11](#all13001-bib-0011){ref-type="ref"}, [12](#all13001-bib-0012){ref-type="ref"}, [13](#all13001-bib-0013){ref-type="ref"}. Colic may be an unrecognized symptom of C1‐INH‐HAE in infancy [28](#all13001-bib-0028){ref-type="ref"}, [29](#all13001-bib-0029){ref-type="ref"}, [30](#all13001-bib-0030){ref-type="ref"}. Early onset of symptoms may predict a more severe subsequent course of disease [3](#all13001-bib-0003){ref-type="ref"}, [14](#all13001-bib-0014){ref-type="ref"}, [15](#all13001-bib-0015){ref-type="ref"}.

### Frequency and severity of symptoms {#all13001-sec-0015}

The frequency and severity of the symptoms exhibit a substantial inter‐ and intraindividual variation. Symptoms often worsen during puberty, particularly in females [3](#all13001-bib-0003){ref-type="ref"}, [14](#all13001-bib-0014){ref-type="ref"}, [31](#all13001-bib-0031){ref-type="ref"}, [32](#all13001-bib-0032){ref-type="ref"}. Onset of symptoms may occur with the introduction of estrogen‐containing medications for acne or birth control [17](#all13001-bib-0017){ref-type="ref"}. The role of puberty in boys is less obvious.

### Trigger factors {#all13001-sec-0016}

A multitude of factors may trigger edematous episodes in C1‐INH‐HAE at any age [33](#all13001-bib-0033){ref-type="ref"}. In children, most attacks occur without a clear trigger. However, the most common attack triggers include mechanical trauma, mental stress, and airway infections [14](#all13001-bib-0014){ref-type="ref"}, [34](#all13001-bib-0034){ref-type="ref"}. Although dental eruption is not a frequent trigger for angioedema attacks, it could act as a provoking factor in some children [34](#all13001-bib-0034){ref-type="ref"}. In adolescent girls, menstruation and ovulation are additional triggers [31](#all13001-bib-0031){ref-type="ref"}. Certain medicines (such as estrogen‐containing oral contraceptives, angiotensin‐converting enzyme inhibitors, ACEIs) can trigger attacks [35](#all13001-bib-0035){ref-type="ref"}, [36](#all13001-bib-0036){ref-type="ref"}.

### Location of symptoms {#all13001-sec-0017}

#### Subcutaneous edema {#all13001-sec-0018}

Subcutaneous edema of the extremities is often the earliest and most common swelling site in pediatric patients [3](#all13001-bib-0003){ref-type="ref"}, [5](#all13001-bib-0005){ref-type="ref"}, [14](#all13001-bib-0014){ref-type="ref"}, [37](#all13001-bib-0037){ref-type="ref"}, [38](#all13001-bib-0038){ref-type="ref"}. Subcutaneous swelling is a common cause of school absenteeism and may affect a child\'s progress in school and participation in sports and other daily activities [14](#all13001-bib-0014){ref-type="ref"}, [34](#all13001-bib-0034){ref-type="ref"}.

#### Submucosal edema {#all13001-sec-0019}

##### Bowel {#all13001-sec-0020}

Bowel wall edema and related symptoms of colicky abdominal pain, nausea, vomiting, and postattack watery diarrhea are common (80--90%) in the pediatric patient population [3](#all13001-bib-0003){ref-type="ref"}, [5](#all13001-bib-0005){ref-type="ref"}, [14](#all13001-bib-0014){ref-type="ref"}, [37](#all13001-bib-0037){ref-type="ref"}. As abdominal pain is frequent in the general pediatric population, the wide differential diagnosis must always be considered including acute appendicitis, mesenteric lymphadenitis, intussusception, partial malrotation with intestinal torsion, Meckel\'s diverticulum, polycystic ovaries, ovarian or testicular torsion, intestinal hemorrhage or infarction, recurrent peritonitis of familial Mediterranean fever, and other abdominal diseases. Afflicted patients are often admitted to a surgical department for observation and at times subjected to an unnecessary operation. Abdominal ultrasound or CT scan may be performed to help exclude acute surgical abdominal disease [29](#all13001-bib-0029){ref-type="ref"}, [30](#all13001-bib-0030){ref-type="ref"}, [39](#all13001-bib-0039){ref-type="ref"}, [40](#all13001-bib-0040){ref-type="ref"}, [41](#all13001-bib-0041){ref-type="ref"}, [42](#all13001-bib-0042){ref-type="ref"}, [43](#all13001-bib-0043){ref-type="ref"}, [44](#all13001-bib-0044){ref-type="ref"}. Abdominal ultrasound may be a sensitive, rapid, and noninvasive differential diagnostic modality in patients with known C1‐INH‐HAE to help differentiate acute appendicitis and monitor response to event intervention with C1‐INH‐HAE therapeutic agents [43](#all13001-bib-0043){ref-type="ref"}, [45](#all13001-bib-0045){ref-type="ref"}, [46](#all13001-bib-0046){ref-type="ref"}. Clinical and ultrasound response to specific C1‐INH‐HAE therapeutic medications helps differentiate C1‐INH‐HAE from non‐C1‐INH‐HAE‐related abdominal events. Standard biochemical and hematological blood tests are often not helpful in abdominal attacks to discriminate C1‐INH‐HAE from non‐C1‐INH‐HAE events. Neutrophilia may occur secondary to an HAE attack [47](#all13001-bib-0047){ref-type="ref"}, [48](#all13001-bib-0048){ref-type="ref"}, [49](#all13001-bib-0049){ref-type="ref"}. Low C4 and low C1‐INH functional levels during an abdominal attack might be retrospectively helpful in confirming that abdominal symptoms are related to C1‐INH‐HAE. Commonly, the results of these tests are not available in time to be of help during the acute event.

##### Upper airway edema (UAE) {#all13001-sec-0021}

It usually first occurs between 11 and 45 years of age, with the mean age of 26. The earliest laryngeal edema recorded has been 3 years of age [14](#all13001-bib-0014){ref-type="ref"}, [50](#all13001-bib-0050){ref-type="ref"}. Although UAE is usually not the first presenting symptom of C1‐INH‐HAE, it may be the first presenting event and this first event may be fatal [50](#all13001-bib-0050){ref-type="ref"}, [51](#all13001-bib-0051){ref-type="ref"}. Death from asphyxiation may occur at any age with mean age at asphyxiation of 40.6 years (range: 9--78 years). Death by asphyxiation is less common in pediatric C1‐INH‐HAE patients [50](#all13001-bib-0050){ref-type="ref"}, [51](#all13001-bib-0051){ref-type="ref"}, [52](#all13001-bib-0052){ref-type="ref"}. Inspection of the larynx is more difficult in young patients and it takes less swelling to asphyxiate in small children because of the smaller upper airway diameter [53](#all13001-bib-0053){ref-type="ref"}, [54](#all13001-bib-0054){ref-type="ref"}, [55](#all13001-bib-0055){ref-type="ref"}. The differential diagnosis in pediatrics includes allergic food reactions, croup, pseudocroup, foreign body aspiration, and acute epiglottitis. For this reason, airway protection is the main task for the emergency department even when specific therapy for C1‐INH‐HAE is not available or it is not promptly administered [56](#all13001-bib-0056){ref-type="ref"}, [57](#all13001-bib-0057){ref-type="ref"}.

#### Other locations {#all13001-sec-0022}

Edema can occur at any site including the urinary bladder, urethra, genitalia, kidneys, muscles, joints, pericardial or pleural spaces and can be associated with neurological symptoms associated with headache, transient visual disturbances, and migraine‐like symptoms in pediatrics [3](#all13001-bib-0003){ref-type="ref"}, [14](#all13001-bib-0014){ref-type="ref"}, [58](#all13001-bib-0058){ref-type="ref"}.

### Prodromal symptoms {#all13001-sec-0023}

Of pediatric patients with C1‐INH‐HAE, 42% to 58% experience prodromal symptoms including erythema marginatum (a map‐like rash on the skin; reported from newborn onward) [4](#all13001-bib-0004){ref-type="ref"}, [6](#all13001-bib-0006){ref-type="ref"}, [14](#all13001-bib-0014){ref-type="ref"}. Skin lesions with a similar appearance may develop in viral and bacterial infections and autoinflammatory diseases including rheumatoid diseases and periodic fever syndromes. The rash may be misdiagnosed as urticaria and C1‐INH‐HAE patients with erythema marginatum have a longer diagnostic delay [27](#all13001-bib-0027){ref-type="ref"}, [59](#all13001-bib-0059){ref-type="ref"}, [60](#all13001-bib-0060){ref-type="ref"}, [61](#all13001-bib-0061){ref-type="ref"}.

### Concomitant disease {#all13001-sec-0024}

A higher incidence of concomitant celiac disease has been observed in C1‐INH‐HAE pediatric patients. In celiac pediatric HAE patients, celiac dietary restriction may reduce abdominal symptoms [62](#all13001-bib-0062){ref-type="ref"}.

Diagnosis {#all13001-sec-0025}
---------

### Prenatal {#all13001-sec-0026}

Prenatal diagnosis may be considered when a disease‐causing mutation has been detected in a C1‐INH‐HAE family. If the family would consider pregnancy termination with the diagnosis of an affected fetus and varying with local ethical restrictions, then prenatal diagnosis of C1‐INH‐HAE may be achieved by chorionic villous sampling or amniocentesis [63](#all13001-bib-0063){ref-type="ref"}. C1‐INH‐HAE has a highly variable disease severity within and between families with poor correlation between gene defect and clinical severity. Advances in therapy have significantly improved the health‐related quality of life (HRQoL) of patients. Therefore, the decision whether to perform prenatal diagnosis should be made by the parents following appropriate counseling and the careful evaluation of benefits and risks. Preimplantation diagnosis and implantation of unaffected fetuses is under consideration in some jurisdictions. No mutation can be detected in the *C1‐INH* (*SERPING1*) gene in 8--10% of C1‐INH‐HAE [64](#all13001-bib-0064){ref-type="ref"}, [65](#all13001-bib-0065){ref-type="ref"}, [66](#all13001-bib-0066){ref-type="ref"}, [67](#all13001-bib-0067){ref-type="ref"}.

### Postnatal {#all13001-sec-0027}

#### Blood laboratory testing {#all13001-sec-0028}

Blood testing to diagnose C1‐INH‐HAE in pediatrics is similar to adults [21](#all13001-bib-0021){ref-type="ref"}. Low functional C1‐INH with low C4 suggests C1‐INH‐HAE at all ages, but requires confirmation. When accompanied by a low antigenic C1‐INH level, then C1‐INH‐HAE type I is possible. If low C4 and low functional C1‐INH are associated with normal or elevated antigenic C1‐INH levels, then C1‐INH‐HAE type II is likely. These testings should be repeated to confirm the diagnosis of C1‐INH‐HAE [68](#all13001-bib-0068){ref-type="ref"}.

Acquired angioedema with C1‐INH deficiency (antibody or C1‐INH consumption‐mediated or B‐cell dyscrasia settings) is usually seen only in adults and is unlikely under 40 years of age. Therefore, C1q is usually not indicated for testing in the pediatric ages. C2, C3, and CH50 testing are not indicated for C1‐INH‐HAE diagnosis at any age. Some immunoregulatory disorders and congenital complement deficiencies other than C1‐INH‐HAE should be kept in mind, however, and further complement investigations may be carried out as clinically indicated particularly if negative family history. C1‐INH‐HAE‐like events have been seen in congenital C4 deficiencies or early‐onset lupus‐like disorders, and in these cases, testing the other complement components may be indicated [69](#all13001-bib-0069){ref-type="ref"}.

In families with known C1‐INH‐HAE, first‐degree relatives, whether symptomatic or asymptomatic, should be screened with C1‐INH (preferably functional) and C4 levels at earliest convenience. The first swelling may be upper airway and may be fatal and come on without warning (Fig. [1](#all13001-fig-0001){ref-type="fig"}A).

![The diagnosis of C1‐INH deficiency in families with known C1‐INH‐HAE (A) and the diagnosis of C1‐INH‐HAE in pediatric patients with angioedema of unknown etiology (B).](ALL-72-300-g001){#all13001-fig-0001}

#### Genetic testing {#all13001-sec-0029}

Genetic testing is not required to confirm the diagnosis of C1‐INH‐HAE unless prenatal testing is considered or in rare cases where a differential diagnosis is required in newborns and infants. Genetic testing may be helpful bearing in mind that not all of the mutations detected by routine genetic testing are undoubtedly disease causing [65](#all13001-bib-0065){ref-type="ref"}. The detection of disease‐associated mutations requires a meticulous analysis of the gene and, possibly, the genetic testing of other affected and disease‐free family members. When genetic testing is available and a known family mutation is detected, then DNA analysis from cord blood or peripheral blood is sufficient to establish the diagnosis (Fig. [1](#all13001-fig-0001){ref-type="fig"}A).

#### Diagnosis under the age of one year {#all13001-sec-0030}

Asymptomatic newborns or infants with a family history of C1‐INH‐HAE should be considered to have hereditary C1‐INH deficiency until the diagnosis is ruled out. C1‐INH levels are normal or even elevated from ages of one to five years compared to adults [70](#all13001-bib-0070){ref-type="ref"}, but before the age of 1 year, the antigenic and functional C1‐INH levels may be lower than in adults, with the lowest levels in umbilical cord blood [71](#all13001-bib-0071){ref-type="ref"}, [72](#all13001-bib-0072){ref-type="ref"}. Both antigenic and functional C1‐INH cord blood levels correspond to 70% and 61.8% of adult normal values increasing to normal adult levels by the age of one year [71](#all13001-bib-0071){ref-type="ref"}, [72](#all13001-bib-0072){ref-type="ref"}. Moreover, neonatal serum complement levels are influenced by birth weight and gestational age [71](#all13001-bib-0071){ref-type="ref"}, [73](#all13001-bib-0073){ref-type="ref"}, [74](#all13001-bib-0074){ref-type="ref"}. In newborns and infants aged less than 1 year, both C1‐INH antigenic level and functional activity are low in the patients with C1‐INH‐HAE type I and are within normal range in non‐C1‐INH‐HAE patients [68](#all13001-bib-0068){ref-type="ref"}, [72](#all13001-bib-0072){ref-type="ref"}. However, under one year of age, C4 levels are frequently low in non‐C1‐INH‐HAE patients as well. Therefore, testing for C1‐INH antigenic and functional levels are helpful to diagnose C1‐INH‐HAE regardless of the age of the patient, but low C4 levels under one year of age are not diagnostic for C1‐INH‐HAE [68](#all13001-bib-0068){ref-type="ref"}.

If C1‐INH antigenic and functional levels are normal in a newborn or infant, the diagnosis of C1‐INH‐HAE is unlikely but confirmation after the age of one year is advisable. If functional and/or antigenic C1‐INH levels are low in a newborn or infant with suspected C1‐INH‐HAE, then we suggest repeating the testing after the age of one year. A final diagnosis requires at least two matching HAE screening results with the second test performed after one year of age [72](#all13001-bib-0072){ref-type="ref"}, [75](#all13001-bib-0075){ref-type="ref"}. If the familial gene is known, then C1‐INH‐HAE diagnosis in a newborn or infant can be helped by genetic testing (Fig. [1](#all13001-fig-0001){ref-type="fig"}A).

#### Diagnostic testing if patient history suggestive of C1‐INH‐HAE, but negative family history {#all13001-sec-0031}

Negative family history does not rule out C1‐INH‐HAE. Clinical suspicion of C1‐INH‐HAE‐like symptoms at any age is an indication for screening regardless of the presence or absence of family history. C1‐INH‐HAE screening includes functional and antigenic C1‐INH levels and C4. If screening is suggestive of C1‐INH‐HAE, a second test should be performed to confirm the diagnosis. If C1‐INH‐HAE is suggested by testing, then all first‐degree relatives in the ascending line should be screened (including symptom‐free individuals). As with many autosomal dominant disorders, 25% of cases may be a *de novo* mutation which may then be passed onto future descendants [76](#all13001-bib-0076){ref-type="ref"}. *SERPING1* gene sequencing may be helpful to confirm the C1‐INH‐HAE in this setting [64](#all13001-bib-0064){ref-type="ref"}, [66](#all13001-bib-0066){ref-type="ref"}. If screening is negative for C1‐INH deficiency, angioedema with acquired C1‐INH deficiency is also excluded, but HAE with normal C1‐INH function, which is very rare in pediatric patients, is not ruled out (Fig [1](#all13001-fig-0001){ref-type="fig"}B).

Management {#all13001-sec-0032}
----------

Diagnosis and management of C1‐INH‐HAE are best achieved through comprehensive care clinics (level III evidence).

### Education and counseling {#all13001-sec-0033}

Education of patients and their family members, family physicians, and consultant specialists including pediatricians with respect to diagnosis and therapy of C1‐INH‐HAE is the cornerstone of successful management of C1‐INH‐HAE in all age groups, but especially in pediatrics (level III evidence) [14](#all13001-bib-0014){ref-type="ref"}, [22](#all13001-bib-0022){ref-type="ref"}, [77](#all13001-bib-0077){ref-type="ref"}, [78](#all13001-bib-0078){ref-type="ref"}, [79](#all13001-bib-0079){ref-type="ref"}. Parents should be provided with comprehensible information on specific characteristics of C1‐INH‐HAE and on management options for all age groups at the time of diagnosis and with each follow‐up comprehensive care HAE clinic visit. Furthermore, distance communication options should be made available including telephone and Internet access to the clinic [14](#all13001-bib-0014){ref-type="ref"}. It is important that teachers and responsible child care workers receive detailed written information on the disease [14](#all13001-bib-0014){ref-type="ref"}, [22](#all13001-bib-0022){ref-type="ref"}. Because young children might not be able to correctly describe their condition, they should always carry a multilingual C1‐INH‐HAE identification and information card containing a description of emergency procedures along with acute treatment products for emergency use (see below for acute treatment options). Alert devices, including identifying wrist or neck bands with emergency contact information, should also be considered [22](#all13001-bib-0022){ref-type="ref"}, [80](#all13001-bib-0080){ref-type="ref"}. A detailed individual action and treatment plan should be provided to the families. Self‐ or assisted treatment techniques should be discussed and training programs for these offered [7](#all13001-bib-0007){ref-type="ref"}, [22](#all13001-bib-0022){ref-type="ref"}, [81](#all13001-bib-0081){ref-type="ref"}.

### Primary prevention {#all13001-sec-0034}

#### Avoidance of C1‐INH‐HAE triggers {#all13001-sec-0035}

As described in Section *Trigger factors* above, some medications may trigger C1‐INH‐HAE events including ACEIs and estrogen‐containing oral contraceptives. These agents should be avoided in C1‐INH‐HAE patients of all ages whenever possible [14](#all13001-bib-0014){ref-type="ref"}, [31](#all13001-bib-0031){ref-type="ref"}, [33](#all13001-bib-0033){ref-type="ref"}, [35](#all13001-bib-0035){ref-type="ref"}, [36](#all13001-bib-0036){ref-type="ref"}. In some cases, attacks can be prevented through counseling, lifestyle changes, and by avoiding triggering factors, most specifically contact sports and other activities involving physical tissue trauma. Although breastfeeding is known to confer protection against numerous diseases, it does not decrease nor prevent C1‐INH‐HAE and its symptoms [82](#all13001-bib-0082){ref-type="ref"}. Immunizations are usually recommended for pediatrics with C1‐INH‐HAE and we suggest the usual schedule for vaccination. The aim of C1‐INH‐HAE management at all ages should be to normalize activities and lifestyle whenever possible. With the availability of modern effective therapeutic and prophylactic interventions, patients should be encouraged to lead as normal a lifestyle as possible. There is no recommendation for specific activity avoidance [34](#all13001-bib-0034){ref-type="ref"}.

#### Genetic management approaches {#all13001-sec-0036}

Gene therapy at various levels and genetic corrective interventions are under study, but not yet available. Preselection of unaffected embryos for implantation is under consideration in some jurisdictions [63](#all13001-bib-0063){ref-type="ref"}.

### Drug treatment {#all13001-sec-0037}

#### Prophylaxis {#all13001-sec-0038}

As indicated above, prophylaxis begins with identification and elimination or avoidance of precipitating factors, if possible [34](#all13001-bib-0034){ref-type="ref"}, [38](#all13001-bib-0038){ref-type="ref"}. Therapeutic prophylaxis usually includes either short‐term prophylaxis (STP) before events that are at an increased risk of precipitating an attack or long‐term prophylaxis (LTP), which would be used to prevent attacks long term. So far, no randomized controlled trials (RCTs) on prophylactic treatment restricted to the pediatric population have been conducted. Few pediatric patients have been included in RCTs (no level I evidence) leaving most pediatric prophylaxis level III evidence [14](#all13001-bib-0014){ref-type="ref"}, [21](#all13001-bib-0021){ref-type="ref"}, [22](#all13001-bib-0022){ref-type="ref"}, [34](#all13001-bib-0034){ref-type="ref"}, [38](#all13001-bib-0038){ref-type="ref"}, [78](#all13001-bib-0078){ref-type="ref"}, [83](#all13001-bib-0083){ref-type="ref"}, [84](#all13001-bib-0084){ref-type="ref"}, [85](#all13001-bib-0085){ref-type="ref"}.

##### Short‐term prophylaxis {#all13001-sec-0039}

As in adults, indications for STP in pediatrics include patient‐specific triggers, medical and dental procedures [85](#all13001-bib-0085){ref-type="ref"}. For most 'minor interventions', the recommendation is to choose on‐demand treatment if a swelling event is precipitated rather than prophylaxis, provided that a licensed on‐demand medication is immediately available in the case of emergency (level III evidence). For interventions that involve airway manipulation or that might lead to tissue swelling, prophylaxis with a dose of 15 to 30 units per kg pdC1‐INH (Berinert^®^ \[pdC1‐INH~Be~\]) concentrate is recommended. There are no studies supporting appropriate timing of the STP nor consensus on the recommended maximum dose (1000 units versus 15 to 30 units/kg) (level III evidence) [14](#all13001-bib-0014){ref-type="ref"}, [21](#all13001-bib-0021){ref-type="ref"}, [22](#all13001-bib-0022){ref-type="ref"}, [34](#all13001-bib-0034){ref-type="ref"}, [78](#all13001-bib-0078){ref-type="ref"}, [83](#all13001-bib-0083){ref-type="ref"}, [84](#all13001-bib-0084){ref-type="ref"}, [85](#all13001-bib-0085){ref-type="ref"}. STP with pdC1‐INH recommendations varies from during procedure or one or more hours before the procedure trying to give as close to the procedure as possible. If licensed on‐demand acute treatment medication is not available with planned procedures, the following treatment options are recommend for STP: oral attenuated androgens (AAs), mainly danazol 2.5 to 10 mg/kg/day, mean dose suggestion 5 mg/kg/day (maximum 600 mg daily) (stanozolol and oxandrolone being used less often); or antifibrinolytics like tranexamic acid (TA) 20 to 50 mg/kg/day split into 2 or 3 doses with a maximum of 3 to 6 g/day, considering dose adjustment for renal impairment (epsilon aminocaproic acid is used less often). Prophylaxis should start (at least) 5 days before and be continued for 2 days postprocedure (level III evidence). As prophylaxis may fail, effective on‐demand treatment should be available whenever possible (level III evidence) [14](#all13001-bib-0014){ref-type="ref"}, [21](#all13001-bib-0021){ref-type="ref"}, [22](#all13001-bib-0022){ref-type="ref"}, [34](#all13001-bib-0034){ref-type="ref"}, [78](#all13001-bib-0078){ref-type="ref"}, [83](#all13001-bib-0083){ref-type="ref"}, [84](#all13001-bib-0084){ref-type="ref"}, [85](#all13001-bib-0085){ref-type="ref"}. In emergency situations and when licensed on‐demand therapies are not available, 10 ml/kg of solvent detergent plasma (SDP) (safer than fresh frozen plasma (FFP)) may be used prophylactically pre‐ or perioperatively or on‐demand (level III evidence).

##### Long‐term prophylaxis {#all13001-sec-0040}

As with adults, indications and options for long‐term prophylaxis (LTP) are controversial for pediatric C1‐INH‐HAE patients. LTP should be considered to minimize the impact of C1‐INH‐HAE on patients' QoL. Agents for LTP include antifibrinolytics (tranexamic acid, TA; epsilon aminocaproic acid), AAs (danazol, stanozolol, oxandrolone), and pdC1‐INH.

Most consider TA to be the agent of choice for LTP in pediatrics, but TA is contraindicated for patients with a history of thromboembolism or a known thrombophilia defect (level III evidence). Patients with a family history of known thrombophilia defect should be screened for the defect before receiving LTP with TA (although the occurrence of thrombotic events is very rare). There are few data regarding the appropriate dose of TA with 20 to 50 mg/kg/day split into 2 or 3 doses with a maximum of 3 to 6 g/day mainly used for LTP (dose adjustment for renal impairment; level III evidence). We recommend starting at the lower dose and increasing as needed to suppress events. When antifibrinolytics fail to achieve the desired improvement or if they are contraindicated or not tolerated, then most recommend pdC1‐INH for LTP (level III evidence).

AAs are usually not considered for LTP in pediatrics prior to Tanner Stage V. After Tanner Stage V, AAs may be used trying to achieve the minimum effective dose. Danazol has been used effectively in pediatrics at doses of 2.5 to 5 mg/kg/day (200 mg daily should not be exceeded). Treatment should start at 2.5 mg/kg/day and increase slowly every 2 weeks until symptom suppression or the maximum tolerated or maximum recommended dose is reached. AA administration requires careful safety monitoring [14](#all13001-bib-0014){ref-type="ref"}, [34](#all13001-bib-0034){ref-type="ref"}. Dosage for oxandrolone has not been established for pediatrics, although some suggest that this is the preferred androgen for pediatric patients. The initial dose for adults is 2.5 mg three times daily and the lowest dose to control the attacks should be reached. Church JA reported the use of 0.1 mg/kg/day in a child and virilizing effects were seen. The drug has to be formulated so decreasing concentrations could be tried (level III evidence) [86](#all13001-bib-0086){ref-type="ref"}, [87](#all13001-bib-0087){ref-type="ref"}.

PdC1‐INH may be the safest LTP approach (level III evidence) and recommended over AA LTP where possible.

LTP does not necessarily mean uninterrupted medication for life. As events change (e.g., changes in stressors or hormonal fluxes), a step‐up, stabilize, step‐down, or intermittent approach to LTP may be a consideration. In general, intermittent LTP may be appropriate in some patients, while others may require continuous LTP (level III evidence). We recommend a pdC1‐INH LTP dose of 10 to 20 units per kg per dose once or twice weekly with an initial maximum dose of 1000 units (level III evidence). The safety and effectiveness of pdC1‐INH has not been established in pediatrics. Three of the 24 subjects in the randomized, placebo‐controlled, cross‐over, routine prophylaxis trial with pdC1‐INH (Cinryze^®^ \[pdC1‐INH~Ci~\]) were under the age of 18 years (9, 14, and 16 years of age). Data on pediatric IV pdC1‐INH LTP dose and frequency are very limited and we are awaiting the results of ongoing pediatric pdC1‐INH~Ci~ study and the results of controlled clinical trials of subcutaneous pdC1‐INH in preventing HAE attacks in this age group. Combination LTP approaches including intermittent LTP or combination LTP agents (e.g., TA plus pdC1‐INH at various doses and frequencies) need further consideration. To date, safety, efficacy, and tolerability of pdC1‐INH appear to be similar in pediatric and adult patients (level III evidence), but approval age and indication of various pdC1‐INH concentrates vary by jurisdiction [14](#all13001-bib-0014){ref-type="ref"}, [21](#all13001-bib-0021){ref-type="ref"}, [22](#all13001-bib-0022){ref-type="ref"}, [34](#all13001-bib-0034){ref-type="ref"}, [78](#all13001-bib-0078){ref-type="ref"}, [83](#all13001-bib-0083){ref-type="ref"}, [84](#all13001-bib-0084){ref-type="ref"}, [85](#all13001-bib-0085){ref-type="ref"}, [88](#all13001-bib-0088){ref-type="ref"}, [89](#all13001-bib-0089){ref-type="ref"}.

#### Acute treatment {#all13001-sec-0041}

All swelling events are eligible for acute treatment (level III evidence) [90](#all13001-bib-0090){ref-type="ref"}.

Upper airway swellings should always receive acute treatment as early as possible followed by immediate assessment in the emergency room. Clinical trials suggest that earlier treatment shortens attack duration and improve treatment outcomes (level III evidence) [91](#all13001-bib-0091){ref-type="ref"}, [92](#all13001-bib-0092){ref-type="ref"}, [93](#all13001-bib-0093){ref-type="ref"}, [94](#all13001-bib-0094){ref-type="ref"}.

Every patient with C1‐INH‐HAE should be considered for home therapy and self‐/caregiver administration training. This can be facilitated through peer‐to‐peer encouragement and training at summer camps with pediatric patients of varied ages or by in‐home nurse training (level I evidence).

Level I evidence for acute treatment of C1‐INH‐HAE has been reviewed for pdC1‐INH~Be~, pdC1‐INH~Ci~, recombinant human C1‐INH (rhC1‐INH) (Rhucin/Ruconest^®^), kallikrein inhibitor ecallantide (Kalbitor^®^), and bradykinin B2 receptor antagonist icatibant (Firazyr^®^) [85](#all13001-bib-0085){ref-type="ref"}, [91](#all13001-bib-0091){ref-type="ref"}, [92](#all13001-bib-0092){ref-type="ref"}, [95](#all13001-bib-0095){ref-type="ref"}, [96](#all13001-bib-0096){ref-type="ref"}, [97](#all13001-bib-0097){ref-type="ref"}, [98](#all13001-bib-0098){ref-type="ref"}, [99](#all13001-bib-0099){ref-type="ref"}. Unfortunately, these treatments have been licensed mainly for adults with pediatric licensing pending and ages for licenses varying by jurisdiction. At present, pdC1‐INH, rhC1‐INH and ecallantide (12 years and up; in Europe and USA, pdC1‐INH~Be~ is licensed for all age groups) are the only agents licensed for pediatric acute treatment [14](#all13001-bib-0014){ref-type="ref"}, [21](#all13001-bib-0021){ref-type="ref"}, [24](#all13001-bib-0024){ref-type="ref"}, [34](#all13001-bib-0034){ref-type="ref"}, [100](#all13001-bib-0100){ref-type="ref"}. There are few reports of use of pdC1‐INH in very young children and babies [101](#all13001-bib-0101){ref-type="ref"}, [102](#all13001-bib-0102){ref-type="ref"}.

##### Plasma‐derived C1‐INH concentrates {#all13001-sec-0042}

The plasma‐derived C1‐INH concentrates (pdC1‐INH~Be~ and pdC1‐INH~Ci~) are both approved for C1‐INH‐HAE acute treatment in pediatric patients in Europe by the EMA (European Medicines Agency) with doses of 20 units per kg for pdC1‐INH~Be~ (pdC1‐INH~Be~ is approved by the EMA and FDA \[Food and Drug Administration\] for all ages and licensed for home/self therapy) and 1000 units for pdC1‐INH~Ci~ (pdC1‐INH~Ci~ is approved in Europe for ages of 12 years and older by the EMA; not approved for acute treatment of HAE attacks in USA). PdC1‐INH~Ci~ is approved by the FDA and EMA for prophylaxis for adolescents and adults and is licensed for home/self‐therapy. In Brazil, pdC1‐INH~Be~ is approved for home/self‐therapy and for pediatric and adult use [95](#all13001-bib-0095){ref-type="ref"}, [99](#all13001-bib-0099){ref-type="ref"}, [103](#all13001-bib-0103){ref-type="ref"}, [104](#all13001-bib-0104){ref-type="ref"}, [105](#all13001-bib-0105){ref-type="ref"}, [106](#all13001-bib-0106){ref-type="ref"}, [107](#all13001-bib-0107){ref-type="ref"}.

##### Ecallantide {#all13001-sec-0043}

Ecallantide is licensed by the FDA for the acute treatment of HAE attacks in patients with C1‐INH‐HAE at the age of 12 years and older (ecallantide is not licensed in Europe). It is administered subcutaneously as a 30 mg dose [97](#all13001-bib-0097){ref-type="ref"}. Hypersensitivity, including anaphylaxis, is a known risk of ecallantide treatment and occurs in 3% of treatments; no deaths are reported [108](#all13001-bib-0108){ref-type="ref"}. Because of the anaphylaxis risk, this drug should be administered only by a healthcare professional who has medical knowledge in the management of anaphylaxis.

##### Recombinant human C1‐INH {#all13001-sec-0044}

rhC1‐INH is licensed by the FDA and EMA for the acute treatment of C1‐INH‐HAE for the patients aged 13 and older [96](#all13001-bib-0096){ref-type="ref"}, [109](#all13001-bib-0109){ref-type="ref"}. An open‐label treatment study with rhC1‐INH in a pediatric population (2--13 years) is ongoing. The dose is 50 units per kg and is given by intravenous injection.

##### Icatibant {#all13001-sec-0045}

Icatibant is licensed for acute treatment (including home/self‐treatment) of C1‐INH‐HAE for ages 18 years or older by the FDA, EMA, ANVISA (Brazil) and other Latin American countries (Table [2](#all13001-tbl-0002){ref-type="table-wrap"}) [91](#all13001-bib-0091){ref-type="ref"}, [92](#all13001-bib-0092){ref-type="ref"}. Icatibant is not licensed for pediatric use, but a clinical trial in pediatric patients is ongoing.

###### 

Therapeutic options---license status

  Drug                                                                      Registration   Indication   Age/Groups   [a](#all13001-note-0004){ref-type="fn"}                                                   
  ------------------------------------------------------------------------- -------------- ------------ ------------ ----------------------------------------- --------------- --------------- --------------- ------
  pdC1‐INH (Berinert^®^)                                                    Europe         ✓            ✓            ---                                       ✓               ✓               ✓               i.v.
  USA                                                                       ✓              ---          ---          ✓                                         ✓               ✓                               
  Latin America (Brazil, Argentina, Mexico, Colombia, Chile, Puerto Rico)   ✓              ✓            ---          ✓                                         ✓               ✓               i.v.            
  Australia                                                                 ✓              ---          ---          ✓                                         ---             ✓               i.v.            
  Canada                                                                    ✓              ---          ---          ---                                       ---             ✓               i.v.            
  Israel                                                                    ✓              ✓            ---          ✓                                         ✓               ✓               i.v.            
  Japan                                                                     ✓              ✓            ---          ✓                                         ---             ✓               i.v.            
  South Korea                                                               ✓              ✓            ---          ✓                                         ✓               ✓               i.v.            
  pdC1‐INH (Cinryze^®^)                                                     Europe         ✓            ✓            ✓                                         ✓               Trial ongoing   ✓               i.v.
  USA                                                                       ---            ✓            ✓            ✓                                         Trial ongoing   ✓                               
  Latin America                                                             ---            ---          ---          ---                                       ---             ---             i.v.            
  Australia                                                                 ---            ✓            ✓            ✓                                         ---             ---             i.v.            
  Canada                                                                    ---            ✓            ✓            ✓                                         ---             ---             i.v.            
  Israel                                                                    ✓              ✓            ✓            ✓                                         ---             ---             i.v.            
  rhC1‐INH (Ruconest^®^)                                                    Europe         ✓            ---          ---                                       ---             Trial ongoing   ✓               i.v.
  USA                                                                       ✓              ---          ---          ---                                       Trial ongoing   ✓                               
  Latin America                                                             ---            ---          ---          ---                                       ---             ---                             
  Icatibant (Firazyr^®^)                                                    Europe         ✓            ---          ---                                       ✓               Trial ongoing   Trial ongoing   s.c.
  USA                                                                       ✓              ---          ---          ✓                                         Trial ongoing   Trial ongoing                   
  Latin America (Brazil, Argentina, Mexico, Colombia)                       ✓              ---          ---          ✓                                         ---             ---             s.c.            
  Australia                                                                 ✓              ---          ---          ✓                                         Trial ongoing   Trial ongoing   s.c.            
  Canada                                                                    ✓              ---          ---          ✓                                         ---             ---             s.c.            
  Israel                                                                    ✓              ---          ---          ✓                                         Trial ongoing   Trial ongoing   s.c.            
  Kuwait                                                                    ✓              ---          ---          ✓                                         ---             ---             s.c.            
  South Africa                                                              ✓              ---          ---          ✓                                         ---             ---             s.c.            
  Attenuated androgens[d](#all13001-note-0007){ref-type="fn"}               Europe         ---          ✓            ✓                                         ---             ---             ✓               Oral
  USA                                                                       ---            ---          ✓            ---                                       ---             ---                             
  Latin America (Brazil, Argentina, Mexico, Colombia)                       ---            ---          ✓            ✓                                         ---             ---             Oral            
  Australia                                                                 ---            ---          ✓            ---                                       ---             ---             Oral            
  Tranexamic acid (Cyklokapron^®^; Transamin^®^; Hemoblock^®^)              Europe         ---          ---          ✓                                         ---             ✓               ✓               Oral
  USA                                                                       ---            ---          ✓            ---                                       ✓               ✓               Oral            
  Canada                                                                    ---            ---          ✓            ---                                       ✓               ✓               Oral            
  Australia                                                                 ---            ---          ✓            ---                                       ✓               ✓               Oral            
  Latin America (Brazil, Argentina, Mexico, Colombia)                       ✓              ---          ---          ✓                                         ---             ---             Oral            
  Ecallantide (Kalbitor^®^)                                                 Europe         ---          ---          ---                                       ---             ---             ---             s.c.
  USA                                                                       ✓              ---          ---          ---                                       ---             ✓                               
  Latin America                                                             ---            ---          ---          ---                                       ---             ---                             

i.v., intravenous; s.c., subcutaneous.

Children aged 0 to ≤12 years.

Adolescents aged 12 to ≤18 years.

Attenuated androgens not licensed in Germany, Austria, and Switzerland.

pdC1‐INH, human plasma‐derived C1‐INH; rhC1‐INH, recombinant human C1‐INH.

John Wiley & Sons, Ltd

##### Plasma {#all13001-sec-0046}

If licensed on‐demand acute treatment medication is not available or not accessible, 10 ml/kg of plasma may be used on‐demand---solvent detergent plasma is preferred over fresh frozen plasma for safety reduction of risk of transfusion transmitted diseases (level III evidence).

Therapeutic options and the license status are summarized in Table [2](#all13001-tbl-0002){ref-type="table-wrap"}.

Home‐based treatment {#all13001-sec-0047}
--------------------

Home therapy for hemophilia has been in use for more than 40 years [85](#all13001-bib-0085){ref-type="ref"}, [110](#all13001-bib-0110){ref-type="ref"}. Home‐based acute treatment and prophylaxis of C1‐INH‐HAE has been recommended for all ages in many consensus documents [22](#all13001-bib-0022){ref-type="ref"}, [84](#all13001-bib-0084){ref-type="ref"}, [85](#all13001-bib-0085){ref-type="ref"}, [111](#all13001-bib-0111){ref-type="ref"}, [112](#all13001-bib-0112){ref-type="ref"}.

Formal approval of various agents for home therapy varies by jurisdiction. Ecallantide, SDP, and FFP are not recommended for self‐therapy because of a small risk of anaphylaxis; however, in‐home therapy by a nurse trained in the treatment of anaphylaxis is an option for ecallantide [22](#all13001-bib-0022){ref-type="ref"}, [90](#all13001-bib-0090){ref-type="ref"}, [111](#all13001-bib-0111){ref-type="ref"}, [112](#all13001-bib-0112){ref-type="ref"}, [113](#all13001-bib-0113){ref-type="ref"}.

Investigators have examined barriers to self‐therapy from the perspective of the nurse [114](#all13001-bib-0114){ref-type="ref"} and physician [111](#all13001-bib-0111){ref-type="ref"}, [112](#all13001-bib-0112){ref-type="ref"}, [114](#all13001-bib-0114){ref-type="ref"} and more recently from the patient perspective [114](#all13001-bib-0114){ref-type="ref"}, [115](#all13001-bib-0115){ref-type="ref"}, [116](#all13001-bib-0116){ref-type="ref"}. All three components of the healthcare system agree that self‐care/self‐home treatment is preferred despite these barriers.

Patients who do not perform self‐treatment tend to overestimate the difficulties of training and of becoming proficient in self‐treatment [116](#all13001-bib-0116){ref-type="ref"}. In contrast, patients who already perform self‐treatment are more confident in their training and their ability to apply both subcutaneous and intravenous injections [116](#all13001-bib-0116){ref-type="ref"}. Although many physicians consider multiple training appointments necessary [112](#all13001-bib-0112){ref-type="ref"}, the majority of patients performing self‐treatment reported that it took them only one or two sessions to feel competent enough for self‐administration.

Confidence is a large factor in patient\'s adherence to treatment and feeling of independence. One of the many benefits of self‐treatment therapy is greater freedom to live a normal life at home, at school or work, or while traveling, leading to improved overall QoL [116](#all13001-bib-0116){ref-type="ref"}, [117](#all13001-bib-0117){ref-type="ref"}, [118](#all13001-bib-0118){ref-type="ref"}, [119](#all13001-bib-0119){ref-type="ref"}.

Comprehensive care centers and follow‐up {#all13001-sec-0048}
----------------------------------------

We recommend following up the patient and family unit at least once per year in an HAE comprehensive care center by a consultant pediatrician C1‐INH‐HAE specialist with access to endocrinology and psychology consultation if needed. For patients on LTP who require closer monitoring, we suggest a monitoring schedule of every three to six months. As with other chronic illnesses, close attention should be paid to growth and development [34](#all13001-bib-0034){ref-type="ref"}. At these visits, the patient diary, outpatient records, discharge summaries, and possible treatment‐emergent adverse events should be reviewed to assess the disease severity and treatment tolerability and to develop or adjust the treatment and prophylaxis strategies. Patients on AA should see an endocrinologist at each visit. Recommendations for adverse event screening while on LTP with AA or TA are similar for pediatric patients as for adults described in recent consensus documents. Between visits, comprehensive care clinic support should be made available via telephone or e‐mail. The exchange of information should be maintained with the family practitioner and/or pediatrician [21](#all13001-bib-0021){ref-type="ref"}, [22](#all13001-bib-0022){ref-type="ref"}. The analysis of HRQoL outcomes at follow‐up visits may help in evaluating therapeutic effectiveness; but it has to be kept in mind that QoL questionnaires currently available for use in C1‐INH‐HAE have been validated only in patients over 17 years of age [120](#all13001-bib-0120){ref-type="ref"}. An adaptation of HAE‐QoL to pediatrics is planned.

International variation in availability of healthcare options and levels of healthcare services {#all13001-sec-0049}
-----------------------------------------------------------------------------------------------

The knowledge about C1‐INH‐HAE diagnosis and therapy, especially in pediatric patients, is still limited, particularly in developing countries. A recent survey about C1‐INH‐HAE in Latin America and the unavailability of data and medications in Latin America as in most African and Asian countries certainly influence the choice of therapy in these countries [11](#all13001-bib-0011){ref-type="ref"}. AAs have been used in pediatrics in many developing countries because of the cost and lack of alternative medications although they are not recommended in the guidelines nor before Tanner Stage V development. In light of this, QoL, morbidity, and the possibility of mortality need to be carefully balanced against the adverse effects of AAs when making the decision to prescribe androgens to pediatric patients [11](#all13001-bib-0011){ref-type="ref"}, [121](#all13001-bib-0121){ref-type="ref"}. Due to the rareness of the disease, emergency departments (EDs) are often unaware of the protocols for treating C1‐INH‐HAE attacks, particularly in pediatrics. Establishing an effective approach to pediatric C1‐INH‐HAE has been a challenge.

A recent publication reported that the average age at the diagnosis of 25 pediatric patients evaluated in the USA was 7.2 years for patients mostly with a known positive family history [5](#all13001-bib-0005){ref-type="ref"}. In Brazil, the mean age at the diagnosis was 8.3 ± 5.1 years with 94% of 50 patients (\<18 years old) being symptomatic (ASG, personal communication presented in the 7th Budapest Workshop) [12](#all13001-bib-0012){ref-type="ref"}.

Even though the patients had a known family history of C1‐INH‐HAE and testing for C1‐INH‐HAE is generally recommended at an age of 1 year in this setting, a diagnosis in these patients was only established after several years [5](#all13001-bib-0005){ref-type="ref"}. Unnecessary procedures are frequently reported in pediatric patients with C1‐INH‐HAE [122](#all13001-bib-0122){ref-type="ref"}. Zilberberg et al. [118](#all13001-bib-0118){ref-type="ref"} evaluated emergency department (ED) visits of C1‐INH‐HAE patients in the United States in 2006 and 2007. During these two years, half of the 221 pediatric patients (\<18 years old) had to be hospitalized due to a C1‐INH‐HAE attack. Because no drugs for attacks had been approved by the FDA at that time, and only FFP was available for attacks, this study could reflect the situation of patients with established C1‐INH‐HAE diagnosis in countries where attack therapy is not available as in most of Latin American, Asian, or African countries. In addition, we should consider the high cost of being treated in the ED in comparison with self‐treatment at home [106](#all13001-bib-0106){ref-type="ref"}.

Estimation of the economic burden associated with C1‐INH‐HAE is difficult and must reflect the costs for medical interventions including hospital and outpatient care, prophylactic and acute therapeutic medications, and also absenteeism of the parents and/or caregivers from work and school absenteeism The true cost of the disease from medications alone in developed countries is frequently in many hundred of thousands of US dollars per year. The cost of the disease in developing countries without specific medications for C1‐INH‐HAE is often excessive absenteeism, significant morbidity, failure to maintain employment, and higher risk of mortality [119](#all13001-bib-0119){ref-type="ref"}, [123](#all13001-bib-0123){ref-type="ref"}.

With the help of a parent or a guardian, pediatric patients have successfully administered pdC1‐INH concentrate, with faster initiation of treatment, less time to symptom relief, and fewer days of hospitalization and days lost from school. In addition, even at a young age, pediatric patients can be taught to safely administer intravenous and subcutaneous therapy as is obvious from data from hemophilic patients [90](#all13001-bib-0090){ref-type="ref"}.

Conclusions {#all13001-sec-0050}
===========

Phase III clinical trials are needed in the pediatric populations so that drug treatments for prophylaxis and acute therapy are approved for all ages. New drug protocols should include pediatric age patients for all rare diseases and use these data to power and develop clinical trials specifically for pediatrics. The future appears that medications will be delivered prophylactically by the subcutaneous and oral routes, which will reduce the stress of frequent intravenous injections. Long‐term follow‐up programs are essential in pediatric patients as these cohorts represent unique populations at risk for adverse events given the growth phases and developmental changes in this population. International registries for pediatric patients with C1‐INH‐HAE disease will facilitate safety and efficacy data and allow earlier detection of long‐term adverse event and benefits of specific interventions. In summary, more therapeutic trials, data on dosing by weight, databases, and data to support self‐administration programs are needed to further the science and clinical care of the pediatric population with C1‐INH‐HAE.
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Werner Aberer, Austria; Sladjana Andrejevic, Serbia; Emel Aygoeren‐Pürsün, Germany; Alena Banerji, USA; Noemi‐Anna Bara, Romania; Murat Bas, Germany; Jonathan Bernstein, USA; Stephen Betschel, Canada; Janne Björkander, Sweden; Isabelle Boccon‐Gibod, France; Laurence Bouillet, France; Maria Bova, Italy; Henrik Halle Boysen, Denmark; Manuel Branco‐Ferreira, Portugal; Anette Bygum, Denmark; Teresa Caballero, Spain; Mauro Cancian, Italy; Anthony Castaldo, USA; Sandra Christiansen, USA; Marco Cicardi, Italy; Christian Drouet, France; Jose Fabiani, Argentina; Mark Gompels, UK; Maria Teresa Gonzalez‐Quevedo, Spain; Jimmy Gooi, UK; Richard Gower, USA; Nihal Mete Gökmen, Turkey; Vesna Grivcheva‐Panovska, Macedonia; Mar Guilarte, Spain; Okan Gülbahar, Turkey; Erik Hack, The Netherlands; Roman Hakl, Czech Republic; György Harmat, Hungary; Miloš Jeseňák, Slovakia; Stephen Jolles, UK; Allen Kaplan, USA; Connie Katelaris, Australia; Mitja Kosnik, Slovenia; Kinga Viktória Kőhalmi, Hungary; Iris Leibovich, Israel; Marcel Levi, The Netherlands; Henry Li, USA; Hilary J. Longhurst, UK; William Lumry, USA; Markus Magerl, Germany; Alejandro Malbran, Argentina; Ludovic Martin, France; Marcus Maurer, Germany; Enikő Mihály, Romania; Dumitru Moldovan, Romania; Mariana Murdjeva, Bulgaria; Imola Beatrix Nagy, Hungary; Erik W. Nielsen, Norway; Sandra Nieto, Mexico; Patrik Nordenfelt, Sweden; Kristine Obtulowitzc, Poland; Maria Pedrosa, Spain; Grzegorz Porębski, Poland; Nieves Prior, Spain; Avner Reshef, Israel; Marc A. Riedl, USA; Bernd Rosenkranz, South Africa; Peter Schmid‐Grendelmeier, Switzerland; Spath Péter, Switzerland; Matthaios Speletas, Greece; Maria Staevska, Bulgaria; Marcin Stobiecki, Poland; Massimo Triggiani, Italy; Nóra Veszeli, Hungary; Walter Wuillemin, Switzerland; Zhi Yu Xiang, China; Beverley Yamamoto, Japan; Bruce Zuraw, USA.

[^1]: See [Appendix](#all13001-app-0001){ref-type="app"} for the members of HAWK.
